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Significance Statement 
 
Studies in transfected cells have established that GPCRs can activate a large 
number of intracellular signaling pathways; however which of these signaling 
pathways are physiologically important is unclear. Here we use a genetically 
engineered mouse to demonstrate a novel role for muscarinic receptor (M3-
mAChR) phosphorylation in airway constriction, with implications for human 
asthma. We add this to the analysis of other M3-mAChR physiological 
responses to generate a map of responses that are either down-stream of G 
protein-dependent signaling or receptor phosphorylation-dependent signaling. 
This map allows us to predict the outcome of novel biased GPCR drugs 
designed to preferentially drive receptor signaling down pathways that 
improve therapeutic efficacy and away from pathways that mediate 
toxic/adverse responses. 
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Abstract 
 
G protein coupled receptors (GPCRs) are known to initiate a plethora of 
signaling pathways in vitro. However, it is unclear which of these pathways 
are engaged to mediate physiological responses. Here we examine the 
distinct roles of Gq/11-dependent signaling and receptor phosphorylation-
dependent signaling in bronchial airway contraction and lung function 
regulated through the M3-muscarinic acetylcholine receptor (M3-mAChR). By 
employing a genetically-engineered mouse expressing a G protein biased M3-
mAChR mutant we reveal the first evidence of a novel role for M3-mAChR 
phosphorylation in bronchial smooth muscle contraction in health and in a 
disease state with relevance to human asthma. Furthermore, this mouse 
model can be used to distinguish the physiological responses that are 
regulated by M3-mAChR phosphorylation (which include control of lung 
function), from those that are down-stream of G protein signaling. In this way 
we present a novel approach by which to predict the physiological/therapeutic 
outcome of M3-mAChR biased ligands with important implications for drug 
discovery. 
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Introduction 
Airflow in the lung is limited by vagally derived acetylcholine that mediates 
airway smooth muscle contraction primarily via activation of M3-mAChRs (1). 
In both asthma and chronic obstructive pulmonary disease (COPD) this 
activity can be up-regulated leading to bronchoconstriction and impaired lung 
function (1) thus explaining the therapeutic benefits provided by anti-
cholinergics, such as tiotropium bromide (2). 
M3-mAChRs can mediate airway smooth muscle contraction through 
both calcium-dependent and calcium-independent mechanisms (1). The 
calcium-dependent mechanism is centred on Gq/11-mediated phospholipase C 
activation generating inositol 1,4,5, trisphosphate that mobilizes calcium from 
the sarcoplasmic reticulum together with promoting extracellular calcium entry 
that ultimately results in a rise in intracellular calcium, activation of myosin-
light chain kinase and the phosphorylation of myosin leading to contraction (3, 
4). In contrast, the mechanism by which M3-mAChR mediates calcium-
independent airway smooth muscle contraction is via activation of the small 
GTPase RhoA, which in turn activates Rho-kinase. The phosphorylation of 
myosin-light chain phosphatase by Rho-kinase decreases enzymatic activity, 
which results in higher levels of phosphorylated myosin and smooth muscle 
contraction (4-6). Although GPCR activation of RhoA is generally considered 
to be via Gq/11 and G12/13 hetero-trimeric G proteins (7) the mechanism by 
which M3-mAChR activates the RhoA pathway is unclear with some indicating 
that this might proceed in a G protein-independent manner and possibly 
involve a direct interaction between the receptor and RhoA (8). The 
prominence of the calcium-independent pathway in excessive airway 
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narrowing (i.e. bronchial hyper-responsiveness) previously observed in animal 
models of allergic bronchial asthma have prompted the suggestion that 
inhibiting the M3-mAChR pathways leading to RhoA activation might be of 
therapeutic potential (9, 10). 
GPCRs become rapidly phosphorylated following agonist stimulation 
and this results in the recruitment of adaptor arrestin proteins that firstly 
uncouple receptors from their cognate G proteins and secondly act as 
signaling scaffolds to drive G protein-independent signaling (11). The 
activation of RhoA-signaling has been identified as one of those pathways 
regulated by receptor phosphorylation/arrestin-dependent signaling (12, 13). 
Since we have shown previously that the M3-mAChR is multiply 
phosphorylated following agonist stimulation (14) and that removal of the 
phosphorylation sites on the receptor results in the uncoupling of the M3-
mAChR from arrestin, and arrestin-dependent processes such as receptor 
internalization (15-17), we wanted to determine if M3-mAChR phosphorylation 
might play a role in calcium-independent airway contraction and therefore 
through this mechanism regulate lung function and airway hyper-
responsiveness. 
In addition, we aimed to establish an experimental system whereby we 
might distinguish between GPCR-mediated physiological responses that are 
down-stream of G protein dependent signaling from those that are down-
stream of receptor phosphorylation/arrestin dependent processes (18, 19). In 
this way we might develop an approach by which to predict the physiological 
action of biased GPCR ligands which may preferentially activate one signaling 
pathway over the other. Such predictive power could be used to rationally 
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design GPCR ligands to possess stimulus bias that promotes signaling via 
pathways that result in therapeutically-beneficial responses in preference to 
those pathways that would result in potentially toxic/adverse responses (18, 
19).  
 In order to achieve this dual aim, we employed here a mouse model 
where the M3-mAChR gene locus has been targeted to express a form of the 
M3-mAChR that is mutated in its phosphorylation sites (16, 17). This mutant 
receptor is uncoupled from phosphorylation-dependent pathways, including 
the recruitment of arrestin (16), but maintains coupling to Gq/11-dependent 
signaling (16, 17). In this regard, this mutant receptor can be considered as G 
protein bias. Using this model we determined a novel role for M3-mAChR 
phosphorylation in the regulation of lung function and in driving allergen-
induced airway hyper-responsiveness. In addition, we were able to include 
this analysis in a map of M3-mAChR physiological responses that lay down-
stream of receptor phosphorylation/arrestin dependent signaling and in this 
way provide a predictive model for the action of biased ligands to the M3-
mAChR. 
 
Results  
Phosphorylation-deficient M3-mAChR mutant is expressed in airway 
smooth muscle and coupled normally to Gq-signaling  
We have previously established that a mutant of the M3-mAChR, where 15 
serine phospho-acceptor sites in the third intracellular loop were mutated to 
alanine, showed reduced levels of agonist-mediated phosphorylation and 
significantly attenuated coupling to arrestin and arrestin-dependent signaling 
	   8	  
whilst maintaining near normal coupling to Gq/11-dependent signaling (16, 17). 
Here, we present further evidence that G protein coupling of the phospho-
deficient M3-mAChR mutant is normal by evaluating the coupling of both wild 
type and mutant receptors to 10 different Gα-subunits in a BRET-based live 
cell assay (20, 21)(Figure 1A). These experiments demonstrated that the 
profile of G protein activation between the wild type M3-mAChR and the 
phospho-deficient mutant was very similar, with both receptor types 
predominantly coupling to Gq (Figure 1B-C). Importantly, there appeared to 
be no significant coupling of the M3-mAChR to G12/13 proteins (Figure 1B-C). 
Control experiments where the receptor was not transfected showed no 
significant activation of G proteins including Gq (Supplementary Figure 
S1A,B). 
A mutant mouse strain (termed M3-KI) was generated where the M3-
mAChR gene locus was modified to express the phospho-deficient M3-
mAChR mutant in place of the wild type receptor (16, 17).  Importantly, the 
levels of the mutant receptor transcript in the lungs from M3-KI mice were 
similar to that of the wild type receptor in C57/BL6 mice as determined by RT-
PCR (Figure 1D). Furthermore, using an in-house antibody to the M3-mAChR 
we found a normal expression profile of the mutant M3-mAChR in airway 
smooth muscle of M3-KI mice as indicated by co-localization of immuno-
staining of the receptor and α-actin in airways (Figure 1E).  
 
M3-mAChR mediates airway smooth muscle contraction in a receptor 
phosphorylation-dependent manner 
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To determine the impact of mutating phosphorylation sites on the M3-mAChR, 
we used precision cut lung slices (PCLS) to monitor bronchoconstriction (22). 
In agreement with previous reports (23), we showed that muscarinic receptor 
stimulation of PCLS from wild type mice resulted in a concentration-
dependent narrowing of the airways (half-maximal response pEC50= 
5.47±0.06, Emax = 82.47±5.82 (Figure 2A-C). In comparison, the 
responsiveness of PCLS from M3-KI mice was significantly reduced both in 
maximal response and potency (pEC50= 4.01±0.06, Emax = 40.79±5.73) 
(Figure 2A-D)(also see; supplementary videos 1 and 2). Importantly, the 
coupling of the phospho-deficient M3-mAChR mutant to Gq/calcium signaling 
in PCLS derived from M3-KI mice was seen to be very similar to that 
observed in wild type PCLS cultures (Figure 2E-G). Thus, despite normal 
coupling to Gq/calcium mobilization the mutant receptor expressed in M3-KI 
lung showed reduced airway contraction indicating an important role for 
receptor phosphorylation-dependent signaling in M3-mAChR-mediated airway 
smooth muscle. 
Since previous studies had established that the RhoA-pathway 
mediates calcium-independent airway smooth muscle contraction (4-6, 24) we 
investigated the role of RhoA signaling downstream of M3-mAChR 
phosphorylation. In vitro analysis of RhoA activation using a FRET-based 
biosensor (Figure 3A) revealed that the phospho-deficient M3-mAChR 
mutant coupled with >200 fold lower potency to the RhoA pathway (pEC50= 
5.41±0.63) than the wild type receptor (pEC50=7.74±0.17) (Figure 3B). 
Furthermore, the RhoA-kinase inhibitor, H1152, reduced the maximal M3-
mAChR contractile response in PCLS by 43% and the potency of 
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acetylcholine-mediated contraction by >10 fold (pEC50 reduced from 
5.07±0.15 to 3.98±0.13 following H1152 treatment)(Figure 3C-E). These data 
indicate that a significant component of the M3-mAChR-mediated airway 
smooth muscle contractile response was independent of Gq/calcium signaling 
but rather was dependent on M3-mAChR phosphorylation and the activation 
of the RhoA-pathway. Consistent with this notion was the fact that inhibition of 
M3-mAChR-mediated Gq/calcium mobilization in PCLS from wild type mice 
using the recently characterized Gq inhibitor, FR900359 (Schmitz et. al. Nat 
Comms In Press) (Figure 3F and Supplementary Figure S2A, B) did not 
affect the M3-mAChR-mediated contractile response (Figure 3G,H).  The 
concentration of FR900359 used in these experiments (30nM) completely 
prevented the carbachol-mediated calcium response in PCLS (Figure 3F) but 
had no effect on carbachol-mediated smooth muscle contraction (Figure 
3G,H).   
 
Lung function and allergen-associated airway hyper-responsiveness is 
dependent on M3 mAChR phosphorylation 
To test if the reduction in contractile response of PCLS obtained from M3-KI 
mice translated to changes in in vivo lung function, lung resistance in 
response to acetylcholine challenge in wild type mice and M3-KI mice was 
monitored. These studies revealed a rightward shift in the potency and a 
decrease in the maximal response of the lung resistance induced by 
administration of acetylcholine in M3-KI mice (Figure 4A). The decrease in 
lung resistance in response to acetylcholine in the M3-KI mice was also 
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reflected in a significant increase in the concentration of acetylcholine 
required to elevate lung resistance by 100% (logPC100)(Figure 4B).  
M3-mAChR signaling through RhoA in airway smooth muscle has been 
closely linked with experimentally induced airway hyper-responsiveness in 
different studies using murine models of allergy (25, 26). We tested here if the 
reduced coupling of the phospho-deficient M3-mAChR mutant to RhoA-
signaling and the subsequent reduction in airway smooth muscle contraction 
observed in M3-KI mice made an impact on allergen induced airway hyper-
responsiveness using a murine model of allergic asthma (27). In these 
experiments wild type mice challenged with saline (0.9% NaCl) showed an 
increase in lung resistance to acetylcholine that was significantly augmented 
in ovalbumin-challenged mice (Figure 4C) – a response defined as classical 
airway hyper-responsiveness (26, 28, 29). However, in contrast to wild type 
mice, ovalbumin-challenged M3-KI mice showed no hyper-responsiveness in 
response to acetylcholine challenge (Figure 4C). The lack of hyper-
responsiveness following ovalbumin sensitization was also reflected by the 
lack of change in the logPC100 value in M3-KI mice following ovalbumin 
challenge. Hence, the logPC100 value fell from 2.38±0.02 in wild type mice 
challenged with saline to 1.68±0.06 after ovalbumin sensitization, indicative of 
airway hyper-responsiveness (Figure 4D). In contrast, the logPC100 value for 
the M3-KI mice was not significantly different between saline and ovalbumin-
treated animals. (Figure 4D). These data indicate that M3-mAChR 
phosphorylation was required in the development of allergen-induced airway 
hyper-responsiveness. 
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The acute ovalbumin-sensitization model used here is associated with 
an inflammatory response as indicated by changes in cytokine levels and 
infiltration of immune cells into the lung. Analysis of cell infiltration by 
assessing total cells in the broncho-alveolar lavage (BAL) fluid determined 
that ovalbumin-induced accumulation of inflammatory cells in to the lung was 
not significantly different between wild type and M3-KI mice (Supplementary 
Figure S3A). Analysis of different inflammatory cell types in the BAL was 
carried out. Whereas the macrophage levels (Supplementary Figure S3B) 
were not seen to change following sensitization of wild type and M3-KI mice, 
the number of eosinophils (Supplementary Figure S3C), neutrophils 
(Supplementary Figure S3D) and lymphocytes (Supplementary Figure 
S3E) were significantly increased, by the same extent, in wild type and M3-KI 
sensitized mice. Hence the inflammatory and immune cell migration into the 
lung following sensitization occurred equally in wild type and M3-KI mice 
indicating that this response was not dependent on M3-mAChR 
phosphorylation. 
 
Phosphorylation of the M3-mAChR regulates specific physiological 
responses  
We show here how use of the G protein biased M3-mAChR mutant receptor 
expressed in M3-KI can be used to define the role of receptor 
phosphorylation-dependent signaling in bronchial airway smooth muscle. We 
reasoned that this approach could be extended to include other M3-mAChR 
mediated responses and in this way a map of the physiological responses that 
lay down-stream of the two fundamental signaling arms of the M3-mAChR, 
	   13	  
namely G protein dependent and phosphorylation/arrestin-dependent 
signaling, could be generated. To test this hypothesis we compared the M3-
mAChR-mediated contraction of bronchial smooth muscle response with other 
M3-mAChR-mediated physiological responses; namely salivary secretion and 
weight gain.  
Previous gene knockout studies established that salivary secretion in 
response to low doses of the muscarinic partial agonist pilocarpine was 
almost completely dependent on M3-mAChR (30). These studies were 
confirmed here where salivary secretion in response to pilocarpine was 
significantly reduced in M3-mAChR-knockout mice (Figure 5A). In contrast, 
salivary secretion in response to pilocarpine in M3-KI mice was significantly 
enhanced when compared to wild type animals (Figure 5A). These results 
indicated that, in contrast to M3-mAChR-mediated contraction of bronchial 
smooth muscle, M3-mAChR-mediated secretion of saliva was independent of 
receptor phosphorylation signaling but rather was dependent on signaling 
through Gq-pathways. The slight increase in salivary secretion observed in 
M3-KI mice may reflect the fact that phosphorylation-dependent mechanisms, 
that are traditionally considered to desensitize G protein responses, are not in 
operation in M3-KI mice.  
M3-mAChR-knockout mice have also previously been reported to show 
reduced food intake and decreased body fat (31). This has been associated 
with the action of the M3-mAChR on the hypothalamic leptin/melanocortin 
system (31). In addition, the M3-mAChR knockout mice showed an increase 
in both resting and total energy expenditure (oxygen consumption) as well as 
an increase in the rate of oxidation of fatty acids (32, 33) - phenotypes that 
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have been linked with M3-mAChR regulation of sympathetic flow (32, 33). 
Disruption of both of these physiological processes in M3-mAChR knockout 
mice combine to generate an overall lean phenotype where the mice show 
reduced total body weight (31, 34). We confirm these data here by 
demonstrating that M3-mAChR knockout mice have reduced body weight 
compared to wild type controls (Figure 5B,C). In contrast to the M3-mAChR 
knockout mice, M3-KI mice were slightly, but significantly, heavier than that 
the of wild type controls (Figure 5B, D). These data suggest that M3-mAChR 
signaling via Gq protein is the primary signaling pathway that regulates M3-
mAChR metabolic and feeding responses responsible for weight gain.  
These data support the notion that GPCRs couple to different signaling 
pathways to mediate specific physiological responses. In the case of the M3-
mAChR, phosphorylation/arrestin signaling regulates bronchial smooth 
muscle contraction, whereas G protein dependent signaling regulates salivary 
secretion and weight gain (Figure 5E). Hence, biased ligands that 
preferentially drive signaling down one pathway over another would be 
expected to mediate specific physiological/therapeutic outcomes. By using a 
genetically-engineered mouse line expressing a G protein biased M3-mAChR, 
we are for the first time able to generate a map of physiological responses 
down-stream of receptor phosphorylation/arrestin signaling and in this way 
offer a predictive model for the action of biased ligands (see; discussion and 
Figure 5F).  
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Discussion 
 
Our study demonstrates a novel role for M3-mAChR phosphorylation in the 
regulation of lung function and in driving airway hyper-responsiveness, one of 
the key features of allergic asthma. Our unique observation also highlights the 
importance of receptor phosphorylation in mediating M3-mAChR-induced 
airway smooth muscle contraction via the activation of RhoA pathway. This 
occurred despite the fact that the Gq/calcium mobilization response to 
acetylcholine in airways from M3-KI mice expressing a phosphorylation 
deficient form of the M3-mAChR was normal. Hence, we were able to 
establish a previously unappreciated role for M3-mAChR phosphorylation-
mediated signaling in bronchoconstriction that was independent of Gq/calcium 
mobilization. 
Since previous studies had demonstrated a role for RhoA signaling in 
calcium-independent airway smooth muscle contraction (4-6, 24), we 
investigated the possibility that phosphorylation of the M3-mAChR was 
involved in coupling the receptor to RhoA signaling and through this 
mechanism to airway smooth muscle contraction. That this was the case was 
indicated by; (i) data showing that pharmacological inhibition of Rho-kinase in 
wild type PLCS pheno-copied the reduced airway contraction response 
observed in PCLS from M3-KI mice and (ii) that the phospho-deficient M3-
mAChR showed markedly reduced coupling to RhoA. Our data are therefore 
consistent with an important role for M3-mAChR phosphorylation in coupling 
to RhoA-signaling, resulting in the contraction of airway smooth muscle by a 
mechanism that proceeds in a manner that is independent of Gq/calcium 
mobilization.  
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It is known that vagally-derived acetylcholine limits airflow by 
bronchoconstriction mediated by the activation of the M3-mAChR on airway 
smooth muscle (1). If the role for M3-mAChR phosphorylation in airway 
smooth muscle contraction identified here is of physiological relevance then it 
might be expected that the lung function of M3-KI mice would be different 
from that of wild type mice. We found that airway obstruction (by assessing 
lung resistance) in response to acetylcholine was significantly reduced in M3-
KI mice compared to wild type mice, an observation consistent with the notion 
that the phosphorylation status of the M3-mAChR is important in regulating 
baseline cholinergic airway smooth muscle tone. This observation is in line 
with studies conducted in healthy volunteers showing a significant 
improvement in lung function by anticholinergic drugs (35). Furthermore, in an 
acute murine model of allergic asthma, which mimics several of the central 
hallmarks of human bronchial asthma (36) including airway hyper-
responsiveness and immune cell lung infiltration, we show that the 
development of allergen-induced airway hyper-responsiveness to 
acetylcholine was dependent on M3-mAChR phosphorylation-dependent 
pathways since sensitized M3-KI mice failed to demonstrate the typical 
enhanced airway hyper-responsiveness. Thus both normal and 
pathophysiological lung function in M3-KI mice was significantly different from 
wild type mice indicating an important role for M3-mAChR phosphorylation in 
the regulation of airway narrowing in health and disease states.  
The mechanisms by which allergen-exposed M3-KI mice were 
protected against the development of abnormal bronchial responsiveness 
appeared to be unrelated to the number of inflammatory cells (eosinophils, 
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lymphocytes and neutrophils) recruited within the airways. This dissociation 
between airway inflammation and the degree of airway hyper-responsiveness 
has been previously reported in various studies including observations in 
asthmatic patients (37) as well as in animal models of allergic asthma (38-40). 
Rather, the mechanism in operation here may be centred on RhoA signalng 
since RhoA expression and activation in airway smooth muscle tissue of 
allergic murine models has previously been shown to be critical to promote 
airway hyper-responsiveness to muscarinic agonists (41, 42) and that 
protection from allergen-induced airway hyper-responsiveness could be 
imparted by the administration of inhibitors of ROCK, the RhoA-regulated 
kinase (25, 26, 29, 43). These observations, together with the fact that 
coupling of the M3-mAChR to RhoA was shown here to be dependent on 
receptor-phosphorylation, strongly raises the possibility that a defect in M3-
mAChR coupling to the RhoA pathway could explain the failure of M3-KI mice 
to develop airway hyper-responsiveness to acetylcholine following allergen 
challenge. We therefore propose that in the lung, phosphorylation of the M3-
mAChR is important in driving key asthmatic features, such as airway hyper-
responsiveness, in part via RhoA-dependent signaling. 
Since our M3-KI mouse line expressing G protein biased M3-mAChR 
mutant defined a novel role for M3-mAChR phosphorylation-dependent 
signaling in airway smooth muscle contraction we reasoned that this mouse 
line could be used to investigate other M3-mAChR-mediated physiological 
responses and establish whether these were dependent on G protein or 
receptor phosphorylation/arrestin-dependent signaling. We therefore 
examined M3-mAChR mediated salivary secretion and weight gain and 
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established that both of these responses were slightly up-regulated in M3-KI 
mice indicating that they were not dependent on receptor 
phosphorylation/arrestin signaling, but more likely dependent on G protein 
coupling. The loss of the phosphorylation-dependent desensitization of G 
protein-mediated signalling may be responsible for the modest but significant 
increase in weight and salivary secretion observed in M3-KI mice.  
These physiological responses could be added to our previous studies 
demonstrating a predominant role for M3-mAChR phosphorylation/arrestin 
coupling in the regulation of insulin secretion (16) and learning and memory 
(17), and G protein coupling in M3-mAChR regulation of p53 subcellular 
localisation and apoptosis (44, 45). By combining all these studies, we have 
generated a map of the physiological responses mediated by the M3-mAChR 
through either G protein or receptor phosphorylation/arrestin-dependent 
signaling (Figure 5E).  
This map has allowed us, for the first time, to make a prediction of the 
likely physiological outcomes of a biased GPCR ligand. Thus, an M3-mAChR 
drug-like ligand showing stimulus bias toward receptor phosphorylation and 
arrestin signaling would preferentially engage physiological signaling 
pathways that would promote changes in insulin secretion, impact on learning 
and memory, and regulate bronchoconstriction (Figure 5F). This same ligand 
would not be expected to have a substantial impact on salivary secretion, 
weight gain and mechanisms associated with cell survival (Figure 5F). This 
analysis has considerable potential application in drug discovery where 
biased ligands can be designed to direct signaling towards those pathways 
that result in clinical efficacy and away from pathways that lead to 
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adverse/toxic outcomes. Hence, by using a genetically modified mouse 
expressing a G protein biased receptor we are not only able to define the 
physiologically-relevant signaling pathways acting down-stream of a particular 
GPCR (in this case the M3-mAChR) but also determine what type of signaling 
bias to design into ligands targeting that receptor in order to promote a 
particular physiological/therapeutic outcome. 
 
Materials and Methods 
See Supplementary information For Materials and Methods 
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Figure 1. Characterization of M3-mAChR expression and calcium 
signaling in the airways of Wild Type and M3-KI mice.  
A. Illustration of the BRET-based biosensor to measure G protein coupling 
where various donor RlucII Gα-subunits can be transfected with an acceptor 
GFP10-Gγ1-subunit together with the M3-mAChR. B-C. Cells were transfected 
with the BRET biosensor consisting of various Rluc- Gα-subunits. Change in 
BRET signal following receptor stimulation with carbachol (100 µM) in cells 
expressing the wild type (B) or phospho-deficient M3-mAChR (C). Data 
represents the mean ±SEM of three independent experiments. D. RT-PCR 
showing the expression profile of M2-, M3- and M4-mAChR RNA in the lungs 
of wild type, M3-KO and M3-KI mice. Expression of actin RNA and omission 
of reverse transcriptase (RT) were used as a control. E. M3-mAChR (green) 
and smooth muscle α-actin immunoreactivity (red) in the airways of wild type, 
M3-KO and M3-KI mice. DAPI (blue) was used to stain nuclei, and overlaid 
images are shown to the right.  
 
Figure 2. M3-mAChR mediated airway smooth muscle contraction is 
dependent on receptor phosphorylation-dependent signaling.  
A. Four representative experiments, two from wild type controls and two from 
M3-KI mice, showing the bronchoconstriction responses to increasing 
concentrations of carbachol in precision-cut lung slices (PCLS). B-D. 
Contractile responses in PCLS derived from wild-type and M3-KI mice. B. 
Mean concentration-response curves to carbachol (CCh) in wild-type and M3-
KI, PCLS. C.  Mean pEC50 and D. mean Emax values calculated from the 
above PCLS concentration-response curves (n=6 in each group). E-F. In 
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precision-cut lung slices (PCLS) from wild type and M3-KI mice, calcium 
responses following acetylcholine (100 µM) stimulation were evaluated. 
Shown are; E. three representative airway responses from PCLS derived from 
wild type mice and F. three representative airway responses from PCLS 
derived from M3-KI mice. G. Average (+ SEM) peak calcium responses from 
representative airways shown in E and F (all responsive single-cells from 
each airway were included in the analysis). Data show is the mean ±SEM and 
analyzed using unpaired T test, ***P<0.001. 
 
Figure 3. M3-mAChR mediated airway smooth muscle contraction is 
dependent on receptor phosphorylation-dependent coupling to RhoA 
signaling 
A. An illustration of the FRET-based biosensor used to detect activated RhoA 
(GTP-bound). B. Rho activity in CHO cells expressing the wild type or the 
phospho-deficient M3-mAChR mutant (M3-KI) following increasing 
concentrations of carbachol (CCh) treatment. Data represents the mean + 
SEM (n=4). Data were analyzed using a two-way ANOVA; *P<0.05, **P<0.01. 
C-E. Effect of Rho-kinase inhibitor H1152 on contractile responses in wild-
type PCLS. C. Mean concentration-response curves to CCh in wild-type 
PCLS pre-treated with vehicle or H1152 (100 nM, 45 min pre-incubation). D. 
Mean pEC50 and E. mean Emax values calculated from the above PCLS CCh 
concentration-response curves in the presence and absence of H1152 (n=12 
in vehicle treated and n=17 in H1152 treated PCLS).  Data in B-D were 
analyzed using unpaired T test, ***P<0.001. F-G. Effects of the Gq-inhibitor, 
FR900359, on carbachol (100 µM) stimulated calcium responses and 
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bronchoconstriction in PCLS from wild type mice.   F. Average (+ SEM) peak 
calcium responses stimulated by carbachol after pre-incubation with 
increasing concentrations of FR900359 (0.3 nM-300nM; 30 min). G. 
Representative examples of carbachol-induced bronchoconstriction in PCLS 
from wild type mice under control conditions (left) or following pre-incubation 
with 30 nM FR900359 (right). H. Mean contractile response to carbachol in 
wild type PCLS following pre-incubation with FR900359 (30 nM; 30 min), 
expressed as a percentage of carbachol-stimulated maximum contraction in 
control slices. 
 
Figure 4. Lung function and airway hyper-responsiveness is regulated 
by M3-mAChR phosphorylation/arrestin signaling 
A. Lung resistance (RL) was measured in wild type (WT) and M3-KI mice at 
various acetylcholine (ACh) concentrations. Data represent the mean ± SEM 
(WT n=10, M3-KI n=13). B. The concentration of acetylcholine required to 
increase lung resistance (RL) by 100% (logPC100) was determined for wild 
type and M3-KI mice. Data presented in A and B are the mean ± SEM (WT 
n=10, M3-KI n=13).  Data were analyzed using Kruskal-Wallis and Mann 
Whitney tests; ***P<0.001 WT vs. M3-KI. C. Airway hyper-responsiveness was 
induced using ovalbumin in WT and M3-KI mice. Lung resistance (RL) was 
determined at various ACh concentrations. Data represent the mean ± SEM 
(WT n=6, M3-KI n=6). Data were analyzed using Kruskal-Wallis and Mann 
Whitney test; *P<0.05 and **P<0.01 WT saline vs. WT ovalbumin, #P<0.05 
and # #P<0.01 WT ovalbumin vs. M3-KI ovalbumin. D. LogPC100 was 
determined for WT and M3-KI mice treated with control saline or ovalbumin. 
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Data present the mean ± SEM (WT n=6, M3-KI n=6).  Data were analyzed 
using Kruskal-Wallis and Mann Whitney tests; **P<0.01 WT saline vs. WT 
ovalbumin, #P<0.01 WT ovalbumin vs. M3-KI ovalbumin.  
 
Figure 5. Mapping M3-mAChR physiological responses mediated by G 
protein and receptor phosphorylation/arrestin dependent signaling. 
A. Salivary secretion in response to pilocarpine (1 mg/kg) administration was 
measured in wild type (WT), M3-KO and M3-KI mice. The data represent the 
mean ± SEM of n=3-6 mice. B. Representative images of M3-KI, M3-KO and 
WT mice demonstrating differences in weight. C. Weight gain in WT and M3-
KO mice. D. Weight gain in WT and M3-KI mice. The data in A, C and D 
represent the mean ± SEM of n=6-11 mice and were analyzed using a two-
way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. E. Illustration of 
the physiologically relevant signaling pathways down-stream of the M3-
mAChR. Some of the pathways known to be activated by the M3-mAChR in 
heterologous systems are illustrated (i.e. PLC, ERK, PKD, JNK, PI3-K, Src, 
RhoA, PLA2 and p53). In this study we used a mutant mouse strain (M3-KI) 
expressing a G protein biased variant of the M3-mAChR to assign those 
physiological responses that were down-stream of either G protein signaling 
(green arrows) or receptor-phosphorylation and arrestin signaling (orange 
arrows). F. Such a map also allows for the rational design of biased ligands 
since our studies present a model by which the physiological/therapeutic 
outcome of biased ligands can be predicted. Thus, for the M3-mAChR, a 
ligand that is biased towards receptor-phosphorylation and arrestin signaling 
would preferentially impact on insulin release, learning and memory and 
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bronchial contraction (orange arrows) whilst having potentially little impact on 
weight gain, salivary secretion and cell death pathways (grey arrows). 
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